Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest Toprol-XL Generics See Quick Substitution Pick-Up

This article was originally published in The Pink Sheet Daily

Executive Summary

Recently launched 100 mg and 200 mg generic strengths capture one-third of scripts.

You may also be interested in...



KV Gets ANDA Approval For Two Strengths Of AstraZeneca’s Toprol-XL

KV believes it has 180-day exclusivity for the 100 mg and 200 mg strengths of the hypertension treatment.

AstraZeneca Releases Toprol-XL “Authorized” Generic Following Sandoz Launch

25 mg dosage strength accounts for 20% of Toprol-XL sales.

AstraZeneca Toprol Patents Are Invalid, Finds Federal Judge

A St. Louis federal court finds both of AstraZeneca’s patents protecting the beta blocker invalid due to double patenting and unenforceable because of AstraZeneca’s “inequitable conduct” with the patent office.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS066450

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel